IL27 and neoplasm: Thus, intra-tumoral delivery of AAV-IL-27 is a feasible approach for enhancing anti-tumor immunity and can be used alone and in combination with anti-PD-1 antibody or T cell adoptive transfer for the treatment of cancer.